Literature DB >> 27132272

Benefit of treatment of latent tuberculosis infection in individual patients.

Kyle Fluegge1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27132272      PMCID： PMC5119636          DOI： 10.1183/13993003.01946-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  10 in total

1.  Genetic polymorphisms, drug metabolism and drug concentrations.

Authors:  Gillian M Shenfield
Journal:  Clin Biochem Rev       Date:  2004

Review 2.  Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?

Authors:  D W Nebert
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

Review 3.  Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis.

Authors:  Jason R Andrews; Farzad Noubary; Rochelle P Walensky; Rodrigo Cerda; Elena Losina; C Robert Horsburgh
Journal:  Clin Infect Dis       Date:  2012-01-19       Impact factor: 9.079

4.  Tuberculosis elimination: theory and practice in Europe.

Authors:  Lia D'Ambrosio; Masoud Dara; Marina Tadolini; Rosella Centis; Giovanni Sotgiu; Marieke J van der Werf; Mina Gaga; Daniela Cirillo; Antonio Spanevello; Mario Raviglione; Francesco Blasi; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2014-01-03       Impact factor: 16.671

5.  A comparative effectiveness analysis of treatment for latent tuberculosis infection using multilevel selection models.

Authors:  Kyle R Fluegge; Brian E Roe
Journal:  J Comp Eff Res       Date:  2015-05-12       Impact factor: 1.744

6.  Benefit of treatment of latent tuberculosis infection in individual patients.

Authors:  Claudia C Dobler; Andrew Martin; Guy B Marks
Journal:  Eur Respir J       Date:  2015-09-24       Impact factor: 16.671

7.  Using Spatial Disease Patterns and Patient-Level Characteristics to Describe Prevalence Elastic Behavior in Treatment for Latent Tuberculosis Infection (LTBI).

Authors:  Kyle R Fluegge
Journal:  Public Health Nurs       Date:  2015-02-06       Impact factor: 1.462

8.  Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.

Authors:  Kyle R Fluegge
Journal:  J Eval Clin Pract       Date:  2014-08-01       Impact factor: 2.431

Review 9.  Towards tuberculosis elimination: an action framework for low-incidence countries.

Authors:  Knut Lönnroth; Giovanni Battista Migliori; Ibrahim Abubakar; Lia D'Ambrosio; Gerard de Vries; Roland Diel; Paul Douglas; Dennis Falzon; Marc-Andre Gaudreau; Delia Goletti; Edilberto R González Ochoa; Philip LoBue; Alberto Matteelli; Howard Njoo; Ivan Solovic; Alistair Story; Tamara Tayeb; Marieke J van der Werf; Diana Weil; Jean-Pierre Zellweger; Mohamed Abdel Aziz; Mohamed R M Al Lawati; Stefano Aliberti; Wouter Arrazola de Oñate; Draurio Barreira; Vineet Bhatia; Francesco Blasi; Amy Bloom; Judith Bruchfeld; Francesco Castelli; Rosella Centis; Daniel Chemtob; Daniela M Cirillo; Alberto Colorado; Andrei Dadu; Ulf R Dahle; Laura De Paoli; Hannah M Dias; Raquel Duarte; Lanfranco Fattorini; Mina Gaga; Haileyesus Getahun; Philippe Glaziou; Lasha Goguadze; Mirtha Del Granado; Walter Haas; Asko Järvinen; Geun-Yong Kwon; Davide Mosca; Payam Nahid; Nobuyuki Nishikiori; Isabel Noguer; Joan O'Donnell; Analita Pace-Asciak; Maria G Pompa; Gilda G Popescu; Carlos Robalo Cordeiro; Karin Rønning; Morten Ruhwald; Jean-Paul Sculier; Aleksandar Simunović; Alison Smith-Palmer; Giovanni Sotgiu; Giorgia Sulis; Carlos A Torres-Duque; Kazunori Umeki; Mukund Uplekar; Catharina van Weezenbeek; Tuula Vasankari; Robert J Vitillo; Constantia Voniatis; Maryse Wanlin; Mario C Raviglione
Journal:  Eur Respir J       Date:  2015-04       Impact factor: 16.671

10.  NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.

Authors:  Junichi Azuma; Masako Ohno; Ryuji Kubota; Soichiro Yokota; Takayuki Nagai; Kazunari Tsuyuguchi; Yasuhisa Okuda; Tetsuya Takashima; Sayaka Kamimura; Yasushi Fujio; Ichiro Kawase
Journal:  Eur J Clin Pharmacol       Date:  2012-11-14       Impact factor: 2.953
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.